Celgene Corporation’s (NASDAQ:CELG) first quarter 2012 earnings (excluding special items but including stock-based compensation expense) of 96 cents per share beat the year-ago earnings by 35%. Higher revenues drove earnings in the reported quarter. The Zacks Consensus Estimate was $1.02 per share.
Quarter in Details
Total revenue climbed 13.2% to $1.27 billion in the first quarter of 2012. Revenues were boosted by the impressive performance of Celgene’s cancer drugs Revlimid, Abraxane and … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards